scholarly journals Quality of Diabetes Care in Patients with Schizophrenia: A Case-Control Study.

2020 ◽  
Author(s):  
mustafa Abdul karim ◽  
Nadeen Wael Al-Baz ◽  
Sami Ouanes ◽  
Ali Khalil ◽  
Ahmed Assar ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Lipid Profile ◽  
Diabetes Care ◽  
Retrospective Chart Review ◽  
Obesity And Diabetes ◽  
Develop Diabetes Mellitus ◽  
Retinal Screening ◽  
Patients With Diabetes ◽  
Retinal Examination ◽  
Quality Of Diabetes Care

Abstract BackgroundPatients with schizophrenia are at least twice as likely to develop diabetes mellitus compared to the general population. This is of significance in Qatar given the high prevalence of obesity and diabetes. Furthermore, the lifespan of people with schizophrenia and diabetes is shortened by approximately15 years due to long-term microvascular and macrovascular complications. High quality diabetes care can significantly reduce morbidity and mortality. We assessed the level of diabetes care delivered to patients with schizophrenia and diabetes compared to those with diabetes alone.MethodsWe performed a retrospective chart review of patients with diabetes mellitus with (n=73) and without (n=73) schizophrenia. Demographic information and electronic medical records were reviewed for 6-month and 1-year American Diabetic Association standards of diabetes care. Optimal diabetes care was defined as having completed glycated hemoglobin (HbA1c), lipid profile and retinal examination within 12 months. ResultsOptimal diabetes care was significantly lower in patients with schizophrenia and diabetes compared to diabetes alone [26.0% (n=19/73) vs 52.1% (n=38/73), p=0.002]. Patients with diabetes and schizophrenia were also significantly less likely to have had body mass index recorded within six months (p=0.008) and HbA1c (p=0.006), lipid profile (p=0.015), estimated glomerular filtration rate (eGFR) (p=0.001) and order for retinal screening (p=0.004) over 12 months. After adjusting for multiple comparisons, only assessment of eGFR (p=0.01) and order for retinal screening (p=0.04) remained significant. ConclusionPatients with schizophrenia and diabetes in Qatar receive sub-optimal diabetes care compared to those with diabetes alone.

scholarly journals Quality of diabetes care in patients with schizophrenia: a case-control study in Qatar

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Mustafa Abdul Karim ◽  
Nadeen Al-Baz ◽  
Sami Ouanes ◽  
Ali Khalil ◽  
Ahmed H. Assar ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Lipid Profile ◽  
Diabetes Care ◽  
Retrospective Chart Review ◽  
Obesity And Diabetes ◽  
Develop Diabetes Mellitus ◽  
Patients With Diabetes ◽  
Retinal Examination ◽  
Quality Of Diabetes Care ◽  
Prevalence Of Obesity

Abstract Background Patients with schizophrenia are at least twice as likely to develop diabetes mellitus compared to the general population. This is of significance in Qatar given the high prevalence of obesity and diabetes. Furthermore, the lifespan of people with schizophrenia is shortened by approximately 15 years, partly due to long-term microvascular and macrovascular complications. High quality diabetes care can significantly reduce morbidity and mortality. We assessed the level of diabetes care delivered to patients in Qatar with schizophrenia and diabetes compared to those with diabetes alone. Methods We performed a retrospective chart review of patients with diabetes mellitus with (n = 73) and without (n = 73) schizophrenia. Demographic information and electronic medical records were reviewed to determine adherence to American Diabetes Association standards of diabetes care in the last 6 and 12 months. Optimal diabetes care was defined as having completed glycated hemoglobin (HbA1c), lipid profile and retinal examination within 12 months. Results Optimal diabetes care was significantly lower in patients with schizophrenia and diabetes compared to diabetes alone [26.0% (n = 19/73) vs 52.1% (n = 38/73), p = 0.002]. Patients with diabetes and schizophrenia were also significantly less likely to have had body mass index recorded within 6 months (p = 0.008) and HbA1c (p = 0.006), lipid profile (p = 0.015), estimated glomerular filtration rate (eGFR) (p = 0.001) and order for retinal examination (p = 0.004) over 12 months. After adjusting for multiple comparisons, only assessment of eGFR (p = 0.01) and order for retinal examination (p = 0.04) remained significant. Conclusion Patients in Qatar with schizophrenia and diabetes, receive sub-optimal diabetes care compared to those with diabetes alone.

The lipid profile of patients with diabetes mellitus in Paionia county

2007 ◽  
Vol 2 (04) ◽  
Author(s):  
S Patiakas ◽  
N Kiriakopoulos ◽  
C Gavala ◽  
I Aggos ◽  
K Akritopoulou ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Lipid Profile ◽  
Patients With Diabetes

scholarly journals Switching from biosimilar (Basalin) to originator (Lantus) insulin glargine is effective in Chinese patients with diabetes mellitus: a retrospective chart review

F1000Research ◽  
2018 ◽  
Vol 7 ◽  
pp. 477 ◽  
Author(s):  
Xia Hu ◽  
Lei Zhang ◽  
Yanhu Dong ◽  
Chao Dong ◽  
Jikang Jiang ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Blood Glucose ◽  
Insulin Glargine ◽  
Hospital Discharge ◽  
Chart Review ◽  
Insulin Dose ◽  
Retrospective Chart Review ◽  
Chinese Patients ◽  
Time Points ◽  
Patients With Diabetes

Background: This study investigated the effectiveness and safety of switching from Basalin® to Lantus® in Chinese patients with diabetes mellitus (DM). Methods:  A retrospective chart review conducted using the electronic medical records of patients hospitalized at the Qingdao Endocrine and Diabetes Hospital from 2005 to 2016. All patients were diagnosed with DM and underwent switching of insulin from Basalin to Lantus during hospitalization. Data collected included fasting (FBG), pre- and post-prandial whole blood glucose, insulin dose, reasons for insulin switching and hypoglycemia. Four study time points were defined as: hospital admission, Basalin initiation, insulin switching (date of final dose of Basalin), and hospital discharge. Blood glucose measurements were imputed as the values recorded closest to the dates of these four time points for each patient. Results: Data from 73 patients (70 patients with type 2 diabetes, 2 with type 1, and 1 undisclosed) were analyzed. At admission, mean glycated hemoglobin (HbA1c) and FBG were 8.9% (SD=1.75) and 9.98 (3.22) mmol/L, respectively. Between Basalin initiation and insulin switch, mean FBG decreased from 9.68 mmol/L to 8.03 mmol/L (p<0.0001), over a mean 10.8 (SD=6.85) days of Basalin treatment, and reduced further to 7.30 mmol/L at discharge (p=0.0116) following a mean 6.6 (7.36) days of Lantus. The final doses of Basalin and Lantus were similar (0.23 vs. 0.24 IU/kg/day; p=0.2409). Furthermore, reductions in pre- and post-prandial blood glucose were also observed between Basalin initiation, insulin switch and hospital discharge. The incidence of confirmed hypoglycemia was low during Basalin (2 [2.4%]) and Lantus (1 [1.2%]) treatment, with no cases of severe hypoglycemia. Conclusion: In this study population, switching from Basalin to Lantus was associated with further reductions in blood glucose, although the dose of insulin glargine did not increase. Further studies are required to verify these findings and determine the reason for this phenomenon.

scholarly journals A szénhidrát-anyagcsere és a gyulladásos folyamatok jellemzésére szolgáló új marker, a szérumprogranulin diagnosztikai és prognosztikai szerepéről

2019 ◽  
Vol 160 (25) ◽  
pp. 973-979
Author(s):  
Bíborka Nádró ◽  
Ferenc Sztanek ◽  
Hajnalka Lőrincz ◽  
Dénes Páll ◽  
György Paragh ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Resistance ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Serum Levels ◽  
Obesity And Diabetes ◽  
Patients With Diabetes ◽  
Factor Α ◽  
Necrosis Factor ◽  
Reduced Renal Function

Abstract: Progranulin is a recently recognized multifunctional glycopeptide shown to be related to obesity and diabetes mellitus. Progranulin is an endogenous antagonist of tumor necrosis factor-α by competitively binding to its receptor, therefore, it exerts anti-inflammatory activity. Paradoxically, previous studies have shown that serum levels of progranulin were elevated in patients with diabetes and associated to its complications including micro- and macroangiopathies, macroalbuminuria or reduced renal function. Moreover, hyperprogranulinemia may be involved in the pathogenesis of obesity-associated insulin resistance. The review summarizes the currently available data on progranulin as a novel marker of the carbohydrate metabolism and inflammation. Orv Hetil. 2019; 160(25): 973–979.

Sign in / Sign up

Export Citation Format

Share Document